←
Biotech Investor2,278 posts
Biotech Investor avatar

Biotech Investor

@learnbiotech

Learn to invest in biotech like the professionals from a former biotech executive and investment banker. For education purposes only. Course on Thinkific

◷ Joined June 2021▧ 1,281 Photos and videos
Biotech Investor avatar
Biotech Investor@learnbiotech·13h

Will orphan drugs become less important to large pharma growth in the future? Orphan drugs (which target patient populations in the US under 200,000) are still key drivers for pharma top-lines #orphandrug It's interesting to see that for some companies, the share of revenue from orphan drugs is declining. LOEs are also driving absolute declines for $BMY and $PFE The largest orphan company $VRTX is diversifying away from orphan only revenue #learnbiotechinvesting #biotech #investing #BiotechPrometheus

Post attachment
Biotech Investor avatar
Biotech Investor@learnbiotech·Nov 15

Investors should keep in mind that a drug on the market after an accelerated approval can later be withdrawn if the confirmatory study doesn't show favorable risk/benefit on an approvable endpoint Here are recent oncology examples but it also happens in other TAs (women's health)

Post attachment
Nature Reviews Drug Discovery avatar
⟳ Biotech Investor retweeted
Nature Reviews Drug Discovery@NatRevDrugDisc·Nov 12

Decision quality in biopharma portfolio renewal nature.com/articles/d41573-0… This article analyses the value the market implicitly assigns to future, still-undisclosed R&D for large pharma companies and discusses how aspects of decision-making could contribute to portfolio renewal

The Biotech Investor avatar
⟳ Biotech Investor retweeted
The Biotech Investor@TheBioInvestor·Nov 10

We ran all 2,020 decisive clinical readouts in our ledger since 2021 to see where biotech trials actually fail. Blinded trial + hard clinical endpoint: 21% miss. Same design on a surrogate: 10%. CNS and cardio are where the money dies. Metabolic is the mirror image. 1/3

Post attachmentPost attachmentPost attachmentPost attachment
Biotech Investor avatar
Biotech Investor@learnbiotech·Nov 6

Since most biotechs aren't profitable they often use warrants (including pre-funded) to raise capital while mitigating short term dilution But what is a warrant and what are their implications? #learnbiotechinvesting #biotech #investing #BiotechPrometheus A warrant is a security that gives the holder the right, but not the obligation, to buy (typically) stock at a certain price Conceptually similar to an option, they both have a strike price and expiry date, but with a few differences (not exhaustive) Many recent biotech follow-ons issue common equity along with "pre-funded" warrants. Why? Investors have ownership concentration limits and a warrant isn't direct ownership before its exercised But pre-funding means the company still gets the cash Either way the warrants are still dilutive and investors should calculate their impact

Post attachmentPost attachment